reNEW – Novo Nordisk Foundation Center for Stem Cell Medicine

Transforming lives with stem cell medicine

The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) is an international collaboration which will pave the way for future stem cell-based treatments.

reNEW focuses on excellent stem cell research and is based on an international tripartite partnership between three leading research institutions: the University of Copenhagen in Denmark, Leiden University Medical Center in the Netherlands, and Murdoch Children’s Research Institute (MCRI). reNEW is led by MCRI’s Chief Scientist and Professor Melissa Little AC.

Visit the reNEW website

The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) is an international collaboration which will pave the way for future stem cell-based treatments.

reNEW focuses on excellent stem cell research and is based on an international...

The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW) is an international collaboration which will pave the way for future stem cell-based treatments.

Visit the reNEW website

The establishment of reNEW has been made possible by the €300 million investment from the Novo Nordisk Foundation, an independent, Danish enterprise foundation that supports scientific, humanitarian and social causes.

The Melbourne node of reNEW is based at MCRI and leverages our expertise in stem cell research in the MCRI Stem Cell Medicine theme.

Our research program aims to translate fundamental stem cell biology discoveries into medical benefits for children and adults living with currently incurable diseases.

Our researchers are experts in stem cells, gene editing, transcriptomics, phosphoproteomics and bioengineering technologies that can be used to model complex disease mechanisms and develop new stem cell-based therapies. Our progress in stem cell research is advanced by the cutting-edge stem cell facilities based at MCRI.

The Novo Nordisk Foundation Center for Stem Cell Medicine, reNEW, is supported by a Novo Nordisk Foundation grant number NNF21CC0073729.

reNEW updates

Novo Nordisk Foundation extends funding of reNEW

The Novo Nordisk Foundation will continue to support regenerative medicine through extended funding for reNEW. Reaching its mid-term at the end of 2026, the Novo Nordisk Foundation have announced that funding will extend to the end of 2031 to enable the consortium to continue to deliver on its Mission.

New biotech company to accelerate treatments for heart disease

Ibnova Therapeutics has emerged from world-first, collaborative research by Murdoch Children’s Research Institute (MCRI) in Melbourne and QIMR Berghofer in Brisbane. Within MCRI, this work is supported by the Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW), which is headquartered in Copenhagen, and has research nodes in the University of Copenhagen, Leiden University Medical Center in the Netherlands and MCRI. Read more on Ibnova Therapeutics launch.

reNEW releases 2025 Annual Report

The Novo Nordisk Foundation Center for Stem Cell Medicine (reNEW),  led by Murdoch Children’s Research Institute (MCRI) Chief Scientist Professor Melissa Little  AC, has released its 2025 annual report..